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INTRODUCTION
Patients with acute respiratory failure (ARF) are frequently treated in Intensive Care Units (ICU), but mortality remains up to 40% (Luhr et al., 1999 , Vincent et al., 2003 . As the mortality rates are related both to the severity of the acute illness and the etiology for ARF (Vincent et al., 2003) , circulating biological markers (biomarkers) may improve patient management by reflecting underlying pathophysiology for future interventions. Of note, established beta-blocker therapy in ARF patients has been reported to be associated with improved outcome (Noveanu et al., 2010) ; thus, it is possible that to identify high-risk patients with myocardial dysfunction early after ICU admission could reduce morbidity and mortality in ARF.
Chromogranin B (CgB) belongs to the chromogranin-secretogranin (granin) protein family (Bartolomucci et al., 2011) , which is a protein family where other members like chromogranin A and secretoneurin previously have been linked to cardiovascular disease (Omland et al., 2003 , Rosjo et al., 2010b , Rosjo et al., 2012b , Ottesen et al., 2015 . Although clustered into the same protein family due to similarities in structure and the ability to bind calcium (Laslop and Mahata, 2002) , there are also individual differences between the granin proteins. For example, CgB is known to bind strongly to the inositol 1,4,5-triphosphate receptor (IP3R), while the other granin proteins cannot bind this intracellular Ca 2+ channel at physiological pH of 7.4 (Thrower et al., 2003) . Moreover, circulating CgB levels, but not other granin proteins, are increased by short-term strenuous physical activity (Rosjo et al., 2013) , possibly due to rapid release of CgB from neuroendocrine cells. Previous publications have also found CgB levels to be increased in the myocardium and plasma during heart failure (HF) development (Rosjo et al., 2010a , Heidrich et al., 2011 . Pertinent to this point, CgB seems to co-localize with natriuretic peptides in atrial cardiomyocytes (Steiner et al., 1990) and to directly regulate basal and angiotensin-II stimulated B-type natriuretic peptide (BNP) production in cardiomyocytes (Heidrich et al., 2008) . Thus, the literature supports an important role for CgB in the myocardium. Also, circulating CgB levels are not influenced by the use of proton pump inhibitors (PPIs), including in patients with heart failure (Rosjo et al., 2010a) . This contrasts the increment in circulating CgA levels associated with PPI use, which may distort a relationship between CgA levels and disease severity, and thereby also supporting CgB as possible superior prognostic biomarker to CgA in a large real-world population of patients with ARF. Accordingly, as massive release of hormonal substances can induce myocardial dysfunction in ARF patients (Dunser and Hasibeder, 2009) and CgB seems to have a low signal-to-noise ratio, we hypothesized that circulating CgB levels could predict outcome in ARF by integrating information from the neuroendocrine system and the myocardium.
MATERIALS AND METHODS

Study design and patient data
This is a prospective substudy of the multi-center observational FINNALI study that included all patients with ARF admitted to 25 Finnish intensive care units (ICUs) during8 weeks (from April 16 th to June 10 th 2007). The FINNALI study has previously been described in detail (Linko et al., 2009) . In short, the FINNALI study included all patients ≥16 years who received >6 h of mechanical ventilation for ARF (invasive or non-invasive) (n=958; Figure   1 ). The onset of ARF was determined as the start of ventilatory support. We collected demographic data, medications, risk factors for ARF, and hemodynamic and ventilatory data daily by an electronic case report form. The clinicians assessed the potential risk factors (during the preceding 48 hours) for ARF and the APACHE III diagnostic system was used to categorize the patients. Simplified Acute Physiology Score (SAPS) II and Sequential Organ Failure Assessment (SOFA) scores were calculated electronically after 24 h in all patients.
The primary endpoint was 90-day all-cause mortality and these data were obtained from Statistics Finland. The Ethics Committee from each participating hospital approved the study before study commencement. The Ethics Committee required informed consent from the patient or a close relative before any blood sampling could take place in the FINNALI Study.
Blood sampling
Blood samples were drawn 6 h after the start of mechanical ventilation (baseline) and on the morning of the second day after admission, after a median of 42 h (day 3). The serum samples were obtained either by venipuncture or from an arterial catheter and stored at -20℃ in each hospital until June 2007. After local storage, the samples were transported to Helsinki University Central Hospital and stored at -80℃ before biomarker analysis (Okkonen et al., 2011) . The levels of CgB in Li-heparin plasma were measured by an in-house radioimmunoassay (RIA) at Uppsala University Hospital, Sweden as previously reported (Rosjo et al., 2010a , Rosjo et al., 2012b , Rosjo et al., 2013 . The circulating CgB levels in Liheparin plasma in healthy subjects have previously in two different studies been reported to be 1200 ± 120 pmol/L (Rosjo et al., 2013) and 1470 (Q1-3 1390-1580) pmol/L (Rosjo et al., 2010a) . N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured by the commercially available proBNP II assay (Roche Diagnostics, Mannheim, Germany) (Okkonen et al., 2011) and chromogranin A (CgA) by a commercially available RIA (EuroDiagnostica AB, Malmö, Sweden) (Stridsberg et al., 2003 , Rosjo et al., 2010a , Rosjo et al., 2012b , Rosjo et al., 2013 . gender; body mass index (BMI); smoking status; history of cardiovascular disease, diabetes mellitus, and chronic obstructive pulmonary disease (COPD); diagnosis for the index hospitalization; baseline heart rate, respiratory frequency and mean arterial blood pressure;
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white blood cell count (WBC); and creatinine, CgA, CgB, and NT-proBNP levels. Variables associated with time to death in univariate analyses were included in the multivariate Cox regression model (backward selection; i.e. all variables were entered into the model and removed one by one if p value >0.10). We also performed Cox bivariate analysis including CgB and SAPS II score and CgB and SOFA score in separate models. WBC, serum creatinine, CgA, CgB and NT-proBNP levels were transformed by the natural logarithm prior to regression analysis due to a right-skewed distribution. Of note, a log-unit increase for admission measurements from the mean value of WBC corresponds to an absolute increase of 5x10 9 /L for WBC, 23.4 umol/L for creatinine, 726 ng/mL for NT-proBNP, 2.3 nmol/L for CgA, and 170 pmol/L for CgB. We calculated the area under the curve (AUC) by receiveroperating characteristics (ROC) statistics to assess prognostic accuracy and the AUCs are presented with 95% confidence intervals (CI). The AUCs are from nested models and presented as recently recommended (Demler et al., 2012) . Reclassification was performed by calculating the category-free net reclassification index (NRI) (Pencina et al., 2011 ) with the basic model built on the clinical variables that were significantly associated with mortality in multivariate Cox regression analysis. This strategy is analogous to the strategy employed in other publications for our group to make basic risk models (Rosjo et al., 2012a , Ottesen et al., 2015 . P values <0.05 were considered significant for all analysis. Statistical analyses were 
RESULTS
Patient characteristics
The flowchart of the FINNALI laboratory study is presented as Figure 1 . The substudy comprised 584 of the 958 patients included into the FINNALI epidemiology study (61%) and a second blood sample was available (after a median of 42 h) in 479 patients (82% of the patients in the laboratory study). The reasons for missing sample on day 3 were early death (n=27), discharge from ICU before day 3 (n=45), or logistic problems/protocol deviations (n=33). In total, 222 patients (38%) were admitted after a surgical procedure. The most common etiology responsible for ARF in our study was cardiovascular disease (n=209; 36%)
followed by gastrointestinal disease (n=69; 12%), pneumonia (n=64; 11%), and neurological disease (n=61; 10%). A total of 169 patients (29%) died during 90 day follow-up and baseline characteristics of the patients stratified according to 90 day mortality are presented in Table 1 .
The patients that died during follow-up were older, had higher prevalence of established cardiovascular disease, more often non-surgical cause for the admission, higher respiratory frequency at baseline, and higher creatinine levels compared to the patients that survived 90 days.
CgB levels in patients with ARF
The The median CgB concentration on day 3 after ICU admission was 872 (Q1-3 726-1088) pmol/L, which was significantly lower compared to admission CgB levels (p<0.001).
CgB levels on day 3 correlated with the same variables as admission CgB levels with the exception of BMI and WBC (Supplementary Table 1) , and CgB levels on day 3 were also influenced by CgA and creatinine levels (Supplementary Table 2 ).
CgB levels and mortality during follow-up
Of the 169 patients who died during follow-up, 77 patients (46%) died during the index hospitalization. CgB levels were higher in non-survivors vs. survivors both on study inclusion Fig. 1 ). Stratifying patients according to CgB quartiles on study inclusion separated patients with a favorable and a poor prognosis ( Fig.2; p<0 .001 by the log rank test). Moreover, admission CgB levels were associated with time to death in univariate Cox regression analysis: HR 3.76 (95% CI 2.89-4.89), p<0.001 (Table 2A) . Other variables available on ICU admission that were associated with time to death in univariate analyses were age, history of chronic heart disease, operative cause of admission, respiratory rate, and creatinine, CgA, and NT-proBNP levels. Adjusting for these variables in multivariable Cox regression analysis, CgB levels were still associated with time to death: HR 2.62 (1.82-3.77), p<0.001 (Table 2B) . Moreover, adding admission CgB levels to a basic risk model of age and NT-proBNP levels improved prognostication as assessed by category-free NRI: 0.50 (95% CI 0.33-0.67), p<0.001. In general, admission CgB levels reclassified patients that experienced no events during follow-up down into a lower risk stratum ( Supplementary Fig. 2 Table 3 ), which both are calculated after 24 h in the ICU. The ROC-AUC for admission CgB levels to separate survivors from non-survivors was 0.72 (95% CI 0.67-0.76), which was comparable to the ROC-AUC of NT-proBNP (Table 3) .
CgB levels on day 3 were also associated with time to death in univariate Cox analysis: HR 2.54 (95% CI 1.50-4.30), p<0.001. The HR for day 3 CgB levels in analysis that adjusted for age, operative cause of admission, history of chronic heart disease and NT-proBNP levels, was 1.72 (1.01-2.94), p=0.05 (Table 2B ). The ROC-AUC for CgB levels on day 3 to separate survivors from non-survivors was 0.60 (0.54-0.66) and the corresponding ROC-AUC for NT-proBNP levels on day 3 was 0.64 [0.59-0.70]) ( Table 3 ).
The median change in CgB levels from admission to day 3 was minus 98 (41 to minus 278) pmol/L and 324 out of the 479 patients with serial CgB measurements demonstrated a decrease in CgB levels. The ROC-AUC for delta (Δ) CgB was 0.62 (0.45-0.68) and the HR for ΔCgB in Cox regression analysis that adjusted for other risk factors was 1.00 (95% CI 1.00-1.001), p=0.05.
DISCUSSION
The main result of this study is that CgB levels, when measured on ICU admission in patients with acute respiratory failure, provided incremental prognostic information to established risk indices, including SAPS II and SOFA scores. Admission CgB levels also reclassified ARF patients into a more correct risk stratum.
The pathobiology mechanisms behind a poor outcome in ARF are complex and not well understood. In the present study 209 of 584 patients (36%) presented cardiovascular risk factors for ARF. Patients with non-cardiovascular causes for ARF may also experience some degree of myocardial dysfunction as hypoxemia, systemic inflammation, capillary leakage, increased intrathoracic pressure, and increased catecholamine levels could influence myocardial function (Ma et al., 2004 , Bajwa et al., 2008 , Khan et al., 2008 , Rengo et al., 2014 . A model of myocardial stress across different etiologies of ARF is supported by the present data that demonstrated universal increment in NT-proBNP levels. Pertinent to this point; other groups have previously reported in an observational study that established β-blocker therapy in ARF patients is associated with improved outcome regardless of the etiology for ARF (Noveanu et al., 2010) . Still, as this was not a randomized controlled study, it is possible that differences between the groups besides β-blocker use could explain this result. Hence, it seems plausible that a large proportion of ARF patients, regardless of etiology, experience myocardial dysfunction and that this dysfunction may be preventable with established cardioprotective therapy. Furthermore, myocardial dysfunction in critical illness seems at least partly related to the release of catecholamines and other hormones into the blood stream (Dunser and Hasibeder, 2009 ). However, these hormones are currently not measured in clinical practice due to lack of stability with large day-to-day and time-of-day fluctuations and the requirement for time-consuming analytical methods to quantify catecholamines and adrenal steroids (Dimsdale and Ziegler, 1991, Bendel et al., 2008) .
Accordingly; a biomarker that can provide stable information on hormonal systems and myocardial function should have potential in patients with ARF. We consider that CgB may represent such a biomarker as circulating CgB levels are increased in situations characterized by systemic and myocardial stress (Rosjo et al., 2010a , Rosjo et al., 2013 and CgB has been found to directly regulate IP3R-mediated Ca 2+ handling in cardiomyocytes in response to angiotensin II-infusion. CgB expression also seems to regulate BNP production in cardiomyocytes exposed to angiotensin II, thus linking CgB levels to important pathophysiology during myocardial dysfunction (Heidrich et al., 2008) . Still, although we and other groups previously have demonstrated increased myocardial CgB production during heart failure development (Rosjo et al., 2010a , Heidrich et al., 2011 , additional organs like neuroendocrine tissue are probably also important contributors to circulating CgB levels in ARF patients. The contribution by non-cardiac tissue may also explain the strong prognostic value of CgB across the total population of ARF patients and not only in patients with CVrelated ARF, which contrasts the results for other members of the chromogranin-secretogranin protein family (Ottesen et al., 2015 , Myhre et al., 2016 .
This is analogous to findings on other granin proteins in critically ill patients, including patients with severe burn injury (Lindahl et al., 2013) , severe sepsis (Rosjo et al., 2012a) and acute heart failure (Ottesen et al., 2015) . Moreover, as we found CgB levels on ICU admission to provide incremental prognostic information to CgA and NT-proBNP levels and other clinical risk factors, a multimarker strategy of established cardiac biomarkers, such as NT-proBNP, and CgB measured on ICU admission could have potential to improve risk assessment in ARF patients. The complementary information by CgB measurements to established risk indices in ARF is also supported by only moderate correlation between admission CgB and NT-proBNP levels, and the ability of admission CgB levels to reclassify patients to their correct risk stratum on top of established risk indices. Moreover, we found that CgB levels measured on day 3 and the change (Δ) in CgB concentrations from admission to day 3 did not provide prognostic information over and beyond the information available by measuring CgB levels on ICU admission.
For a biomarker to have clinical utility, the biomarker should help the physician to treat the patients better (Morrow and de Lemos, 2007) . One example is NT-proBNP since elevated NT-proBNP levels are known to reflect myocardial dysfunction, especially related to volume overload and ventricular stress in critically ill patients (Omland, 2008) . Of note, the administration of intravenous fluids seems to influence NT-proBNP levels (Omland, 2008) . In contrast, less information is available on the pathophysiology related to high CgB levels in patients with ARF. We found admission CgB levels to be associated with CgA and creatinine levels and a combination of endocrine, myocardial, and renal dysfunction could influence CgB levels, with reduced clearance probably the reason why CgB levels are increased in patients with impaired renal function. Of note, renal dysfunction has also previously been found to increase circulating granin protein levels in other critically ill patients, including patients with severe sepsis (Rosjo et al., 2012a) and acute heart failure (Ottesen et al., 2015) .
However, as the majority of variation in circulating CgB levels in patients with ARF on ICU admission was not accounted for in the FINNALI Study database, and given the associations between granin proteins and myocardial function and hormonal status (Bartolomucci et al., 2011 , Sabban et al., 2012 , Rosjo et al., 2013 , it is plausible that these variables explain at least part of the missing pathophysiology for CgB levels in ARF patients. However, there is a need for additional experimental and clinical studies to establish the exact pathophysiology reflected by elevated circulating CgB levels in ARF patients.
Study strengths and limitations
The strengths of this study include the multicenter design and the size of the population. The external validity of the results is also supported by baseline characteristics of the patients included into this FINNALI substudy being comparable to the baseline characteristics of the population included into the total FINNALI cohort (Okkonen et al., 2011) . The CgB analysis was conducted in a standardized way at a single center. Our study also has some limitations.
First, the lack of detailed information on myocardial function from echocardiography or magnetic resonance imaging is a limitation, but imaging was not feasible to be performed in a standardized way in such a large epidemiological study comprising patients from 25 ICUs.
Second, we also lacked information about the cause of death in our patients. Third, although
we previously have demonstrated only weak correlations between CgB and cardiac troponin levels (Rosjo et al., 2010a , Rosjo et al., 2013 , the lack of cardiac troponin measurements in this study is a limitation. Fourth, detailed information on proton pump inhibitor use prior to hospital admission, which has been shown to increase levels of CgA (Waldum et al., 1996) , was not available in the FINNALI Study.
There is also a need to establish the reference concentrations of CgB in a healthy population as previous reports have included only a low number of subjects, which precludes also assessment whether CgB levels may differ according to age and gender. There is also a need to establish the reference concentrations of CgB in a healthy population as previous reports have included only a low number of subjects, which precludes also assessment whether CgB levels may differ according to age and gender.
CONCLUSION
In this laboratory substudy from the large FINNALI Study, we found CgB levels measured on ICU admission to provide additional prognostic information to established risk indices in patients with ARF, including SAPS II and SOFA scores. CgB levels on ICU admission also reclassified patients into more correct risk strata on top of established risk models. Still, additional studies are needed to validate our results and there is also a need for more information regarding the pathophysiology reflected by high CgB levels in patients with ARF. Fig. 1 Flow chart of the study Fig. 2 
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